Holdings
Venrock Adviser, LLC
As of Sep 30, 2026, Venrock Adviser, LLC reported 31 positions worth US$1.82B. Largest: Oruka Therapeutics, Inc., Erasca, Inc. and Spyre Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Oruka Therapeutics, Inc. | 4.15M | US$346M | no change | Sep 30, 2026 |
| Erasca, Inc. | 20.1M | US$295M | +2.2M | Sep 30, 2026 |
| Spyre Therapeutics, Inc. | 2.49M | US$221M | −500K | Sep 30, 2026 |
| Savara, Inc. | 19.6M | US$101M | +4.82M | Sep 30, 2026 |
| Ocular Therapeutix, Inc. | 10.3M | US$79.4M | no change | Sep 30, 2026 |
| Dianthus Therapeutics, Inc. | 822K | US$72.4M | −358K | Sep 30, 2026 |
| Viridian Therapeutics, Inc. | 3.26M | US$67.1M | no change | Sep 30, 2026 |
| Vor Biopharma Inc. | 3.04M | US$58M | no change | Sep 30, 2026 |
| Cogent Biosciences, Inc. | 1.64M | US$52.6M | no change | Sep 30, 2026 |
| Adlai Nortye Group Ltd. | 3.21M | US$51.4M | new | Sep 30, 2026 |